HEALWELL's Pentavere Publishes Study in the Journal of Liquid Biopsy; Validating DARWEN(TM) AI as a Leading Artificial Intelligence Clinical Decision Support Tool in Oncology
HEALWELL AI's subsidiary Pentavere has published a groundbreaking study in the Journal of Liquid Biopsy, demonstrating the effectiveness of their DARWEN™ AI platform in oncology care. The study, conducted with Princess Margaret Cancer Centre, shows the platform achieves a 100-fold improvement in processing time compared to manual methods when analyzing complex next-generation sequencing and liquid biopsy reports.
The research validates DARWEN™ AI as a leading clinical decision support tool for identifying actionable genomic alterations in lung cancer patients, enabling faster personalized treatment initiation. This is particularly significant as lung cancer is the second most common cancer and leading cause of cancer-related deaths worldwide. The study highlights how liquid biopsies, using blood tests instead of surgical procedures, can accelerate cancer treatment and personalized care.
La sussidiaria di HEALWELL AI, Pentavere, ha pubblicato uno studio innovativo nel Journal of Liquid Biopsy, dimostrando l'efficacia della loro piattaforma AI DARWEN™ nella cura oncologica. Lo studio, condotto in collaborazione con il Princess Margaret Cancer Centre, mostra che la piattaforma raggiunge un miglioramento di 100 volte nel tempo di elaborazione rispetto ai metodi manuali nell'analisi di report complessi di sequenziamento di nuova generazione e biopsie liquide.
La ricerca convalida DARWEN™ AI come uno strumento principale di supporto alle decisioni cliniche per identificare alterazioni genomiche azionabili nei pazienti affetti da cancro ai polmoni, consentendo un avvio più rapido dei trattamenti personalizzati. Questo è particolarmente significativo poiché il cancro ai polmoni è il secondo tipo di cancro più comune e la principale causa di morte per cancro nel mondo. Lo studio evidenzia come le biopsie liquide, utilizzando test del sangue anziché procedure chirurgiche, possano accelerare il trattamento del cancro e la cura personalizzata.
La subsidiaria de HEALWELL AI, Pentavere, ha publicado un estudio innovador en el Journal of Liquid Biopsy, demostrando la efectividad de su plataforma de IA DARWEN™ en el cuidado oncológico. El estudio, realizado en colaboración con el Princess Margaret Cancer Centre, muestra que la plataforma logra una mejora de 100 veces en el tiempo de procesamiento en comparación con los métodos manuales al analizar informes complejos de secuenciación de nueva generación y biopsias líquidas.
La investigación valida a DARWEN™ AI como una herramienta líder de apoyo a la decisión clínica para identificar alteraciones genómicas accionables en pacientes con cáncer de pulmón, permitiendo un inicio más rápido del tratamiento personalizado. Esto es particularmente significativo ya que el cáncer de pulmón es el segundo tipo de cáncer más común y la principal causa de muertes relacionadas con el cáncer en todo el mundo. El estudio destaca cómo las biopsias líquidas, utilizando análisis de sangre en lugar de procedimientos quirúrgicos, pueden acelerar el tratamiento del cáncer y la atención personalizada.
HEALWELL AI의 자회사인 Pentavere가 Journal of Liquid Biopsy에 혁신적인 연구 결과를 발표하여 그들의 DARWEN™ AI 플랫폼이 종양학 치료에서 효과적임을 입증했습니다. 이 연구는 Princess Margaret Cancer Centre와 협력하여 수행되었으며, 플랫폼이 복잡한 차세대 시퀀싱 및 액체 생검 보고서를 분석할 때 수동 방법에 비해 100배 개선된 처리 시간을 달성한다는 것을 보여줍니다.
이 연구는 DARWEN™ AI가 폐암 환자에서 실행 가능한 유전체 변화를 식별하기 위한 주요 임상 의사 결정 지원 도구로서의 역할을 검증하며, 개인 맞춤형 치료 개시를 더 빠르게 할 수 있도록 합니다. 이는 폐암이 두 번째로 흔한 암이며 전 세계적으로 암 관련 사망의 주요 원인이라는 점에서 특히 중요합니다. 이 연구는 수술 절차 대신 혈액 검사를 사용하는 액체 생검이 암 치료 및 개인 맞춤형 치료를 가속화할 수 있는 방법을 강조합니다.
La filiale de HEALWELL AI, Pentavere, a publié une étude révolutionnaire dans le Journal of Liquid Biopsy, démontrant l'efficacité de leur plateforme AI DARWEN™ dans les soins oncologiques. L'étude, menée en collaboration avec le Princess Margaret Cancer Centre, montre que la plateforme atteint une amélioration de 100 fois du temps de traitement par rapport aux méthodes manuelles lors de l'analyse de rapports complexes de séquençage de nouvelle génération et de biopsies liquides.
Cette recherche valide DARWEN™ AI en tant qu'outil principal de soutien à la décision clinique pour identifier les altérations génomiques exploitables chez les patients atteints de cancer du poumon, permettant un démarrage plus rapide des traitements personnalisés. Cela est particulièrement significatif car le cancer du poumon est le deuxième cancer le plus fréquent et la principale cause de décès liés au cancer dans le monde. L'étude met en évidence comment les biopsies liquides, utilisant des tests sanguins au lieu de procédures chirurgicales, peuvent accélérer le traitement du cancer et les soins personnalisés.
Die Tochtergesellschaft von HEALWELL AI, Pentavere, hat eine bahnbrechende Studie im Journal of Liquid Biopsy veröffentlicht, die die Wirksamkeit ihrer DARWEN™ AI-Plattform in der Onkologie belegt. Die Studie, die in Zusammenarbeit mit dem Princess Margaret Cancer Centre durchgeführt wurde, zeigt, dass die Plattform eine 100-fache Verbesserung der Verarbeitungszeit im Vergleich zu manuellen Methoden bei der Analyse komplexer Next-Generation-Sequenzierungs- und Flüssigbiopsieberichte erzielt.
Die Forschung validiert DARWEN™ AI als ein führendes klinisches Entscheidungsunterstützungstool zur Identifizierung umsetzbarer genomischer Veränderungen bei Lungenkrebspatienten, was einen schnelleren Beginn der personalisierten Behandlung ermöglicht. Dies ist besonders bedeutend, da Lungenkrebs die zweithäufigste Krebsart und die häufigste Todesursache bei krebsbedingten Todesfällen weltweit ist. Die Studie hebt hervor, wie Flüssigbiopsien, die Blutuntersuchungen anstelle chirurgischer Eingriffe verwenden, die Krebsbehandlung und personalisierte Pflege beschleunigen können.
- DARWEN™ AI platform demonstrates 100-fold efficiency improvement over manual processes
- Successfully validated as clinical decision support tool for cancer treatment
- Partnership with prestigious Princess Margaret Cancer Centre
- Platform enables faster identification of genomic alterations for personalized treatment
- None.
- The use of the DARWEN™ AI platform achieved time savings representing a 100-fold improvement as compared to traditional manual processes(1), demonstrating the opportunity to advance care and improve patient outcomes by leveraging cutting edge AI technology in clinical care.
- This study was conducted in collaboration with Princess Margaret Cancer Centre and is one of the world's first peer-reviewed studies to use an artificial intelligence platform to demonstrate the value of liquid biopsies in speeding up lung cancer treatment in patients without actionable genomic alterations. Lung cancer is the second most common cancer and the leading cause of cancer-related deaths worldwide(2). Liquid biopsies offer a less invasive alternative to traditional biopsies by using blood tests instead of surgery.
- This research further validates Pentavere's DARWEN™ AI system as a leading clinical decision support tool, enabling fast and accurate data extraction from complex next-generation sequencing ('NGS') and liquid biopsy reports to identify actionable genomic alterations and start personalized treatments faster.
- Building on previous publications, Pentavere's DARWEN™ AI platform is transforming cancer care, driving personalized treatment, and advancing the future of precision medicine by harnessing world-class artificial intelligence technology.
Toronto, Ontario--(Newsfile Corp. - February 13, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce that its subsidiary, Pentavere Research Group ("Pentavere"), a globally recognized AI digital health company, has recently published a study in the 'Journal of Liquid Biopsy' that highlights how liquid biopsies can accelerate cancer treatment and personalized care for lung cancer patients, validating DARWEN™ AI as a leading Artificial Intelligence Clinical Decision Support Co-Pilot in Oncology.
Aaron Leibtag, CEO and Co-Founder of Pentavere, stated, "Clinicians and researchers frequently cite the time required to generate high-quality real-world data as a major barrier to advancing medical innovation for patients. This study is a further example showcasing how Pentavere's DARWEN™ AI system overcomes this challenge as a world-leading clinical decision support tool, delivering rapid, accurate data at scale and enabling more inclusive, impactful healthcare decisions."
This study was conducted in collaboration with Princess Margaret Cancer Centre of Toronto, Ontario, and is one of the world's first peer-reviewed studies to use an artificial intelligence platform to demonstrate the value of liquid biopsies in guiding and speeding up lung cancer treatment in patients without actionable genomic alterations. The study data comes from complex, multi-page Next Generation Sequencing (NGS) and liquid biopsy reports with results for hundreds of genes and thousands of genomic alterations per patient delivered to treating hospitals in PDF format. Without DARWEN™ AI, the time to manually review thousands of pages of complex data to generate the data set used for this study would have taken 100 times longer(1).
This study further validates Pentavere's DARWEN™ AI system as a critical clinical decision support tool, enabling fast and accurate data extraction from NGS and liquid biopsy reports to identify actionable genomic alterations and start personalized treatments faster. Building on previous publications, Pentavere's DARWEN™ AI system is transforming cancer care, driving personalized treatment, and advancing the future of precision medicine.
Lung cancer ranks as the second most prevalent cancer and the leading cause of cancer-related deaths globally(2). Liquid biopsies provide a less invasive alternative to traditional methods, utilizing blood tests rather than surgical procedures.
Footnotes:
- https://pubmed.ncbi.nlm.nih.gov/35719866/
- https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html
Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI Inc.
About HEALWELL AI
HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit https://healwell.ai/.
About Pentavere
Pentavere Research Group is a globally recognized and award-winning AI digital health company that has built a best-in-class AI engine to identify patients that are eligible for approved medications or interventions, to improve outcomes for patients and help drive therapy growth and penetration. Pentavere's AI system, DARWEN™, identifies patients that are eligible for but not receiving approved medications or interventions, improving outcomes for patients and helping drive appropriate therapy growth and penetration. For more information, visit: http://pentavere.ai/.
Forward-Looking Statements
Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws, including statements about the potential impact of Pentavere's AI on treatment times and patient outcomes; and potential applications for Pentavere's research and AI capabilities and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as "enabling", "building on", "advancing", "driving", "transforming" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: the stability of general economic and market conditions; sufficiency of working capital and access to financing; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; trends in customer growth and the adoption of new technologies in the industry; technologies working as anticipated; anticipated viewership and impact of the publication; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.
Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated April 1, 2024, which is available under HEALWELL's SEDAR+ profile at www.sedarplus.ca. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
For more information:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
ir@healwell.ai
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240746
FAQ
What efficiency improvement does HEALWELL's DARWEN AI (HWAIF) demonstrate in the new study?
How does HEALWELL's DARWEN AI (HWAIF) improve lung cancer treatment?
What is the significance of HEALWELL's (HWAIF) liquid biopsy study?
Who collaborated with HEALWELL (HWAIF) on the liquid biopsy study?
